In a major milestone for chronic kidney disease treatment, Vera’s Trutakna drug gets FDA approval as a weekly injectable kidney drug. Manufactured by Vera Therapeutics, Trutakna is a drug that reduces proteinuria in adults with primary IgA nephropathy.
Recognizing its profound therapeutic potential, Vera Therapeutics’ Trutakna got an accelerated FDA approval. The FDA had previously granted the drug an Application Priority Review and Breakthrough Therapy designation.
Vera Therapeutics’ kidney disease drug is the first-ever therapy capable of simultaneously targeting two critical immune system proteins: BAFF and APRIL. Rather than merely managing downstream symptoms, it addresses the underlying immune pathway driving the condition.
Clinical evidence from this drug shows a meaningful reduction in urine protein levels, offering new hope while confirmatory studies continue to assess long-term kidney protection.
Dr. Marshall Fordyce, founder and CEO of Vera Therapeutics, noted that “the company reached an agreement with the FDA to conduct the final analysis earlier than originally scheduled due to the drug’s sustained impact on kidney function stability.”
What is IgA Nephropathy?
Primary IgA nephropathy, also known as Berger’s disease, is a serious, progressive autoimmune condition where abnormal IgA antibodies accumulate within the kidneys. This abnormal buildup triggers severe localized inflammation, leading to progressive kidney damage over time.
For decades, managing this progressive disease has presented severe challenges due to a lack of targeted, disease-modifying options. Patients frequently had to rely on high-dose steroids, which carry toxic side effects. This created an urgent medical demand for a novel kidney disease therapy capable of intervening early in the disease pathway to protect kidney function before irreversible organ harm occurs.
Vera Therapeutics’ Trutakna and Existing Treatments
As a first-in-class BAFF and APRIL inhibitor, Trutakna introduces an innovative mechanism of action to the nephrology space. BAFF (B-cell activating factor) and APRIL (A proliferation-inducing ligand) are signaling proteins that drive the survival, maturation, and proliferation of the immune cells responsible for creating abnormal antibodies.
By acting as a recombinant fusion protein, Trutakna achieves a dual inhibition that simultaneously blocks both proteins. This dual mechanism successfully shuts down the production of the disease-causing, abnormal IgA antibodies at the source.
Intervening so far upstream in the immune cascade marks an important therapeutic advancement over older treatments that merely manage downstream inflammation or blood pressure.
Full FDA Approval for Vera Therapeutics’ Trutakna Still Needed
While Vera’s Trutakna drug gets FDA approval, it is not traditional or final approval. The ongoing ORIGIN Phase 3 study is actively evaluating long-term impacts on kidney function.
In the clinical trial, patients treated with Trutakna achieved an average 46% reduction in proteinuria from baseline after 36 weeks of treatment, resulting in an approximately 42% placebo-adjusted reduction.
Because Trutakna modulates the immune system, it carries an increased risk of infections. Physicians are advised to assess patients for active infections before initiating therapy and monitor them closely during treatment. Vaccine precautions are also mandatory, meaning the administration of live vaccines is not recommended within 30 days before or during the use of Vera Therapeutics’ kidney disease drug.
Confirmatory data are now expected in the third quarter of 2026, ahead of the original 2027 timeline. Successful long-term clinical outcomes from this study will allow Vera to convert this accelerated status into full FDA drug approval.
Next Step After Vega’s Trutakna FDA Approval
Vera Theraputics announced an immediate commercial launch, stating that physicians can write prescriptions immediately, with patient availability expected within three to four weeks. The company disclosed a wholesale acquisition cost of $32,700 for a 28-day supply, translating to an annual price of $425,000.
Vera aims to differentiate Trutakna based on its upstream dual-target immune mechanism and placebo-like safety profile rather than relying on direct cross-trial efficacy comparisons.
With the approval, Vera’s dual inhibitor Trutakna enters an arena alongside recent entries such as Novartis‘ Fabhalta and Otsuka’s Voyxact.
New Hope For Kidney Disease Care
As Vera’s Trutakna drug gets FDA approval, it opens the door to more personalized treatment options for individuals living with chronic kidney disease. The potential to intervene early before irreversible kidney damage occurs completely alters the trajectory of standard care.
